Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLNCF) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Silence Therapeutics (SLNCF) over the last 6 years, with Q3 2025 value amounting to $3000.0.

  • Silence Therapeutics' Capital Expenditures rose 10471.21% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $117000.0, marking a year-over-year decrease of 1122.7%. This contributed to the annual value of $211000.0 for FY2024, which is 27678.57% up from last year.
  • Latest data reveals that Silence Therapeutics reported Capital Expenditures of $3000.0 as of Q3 2025, which was up 10471.21% from $48000.0 recorded in Q2 2025.
  • Silence Therapeutics' Capital Expenditures' 5-year high stood at $2.8 million during Q4 2021, with a 5-year trough of -$613602.7 in Q2 2021.
  • Its 5-year average for Capital Expenditures is $115614.4, with a median of -$8152.4 in 2021.
  • In the last 5 years, Silence Therapeutics' Capital Expenditures tumbled by 143735.51% in 2021 and then surged by 216419.74% in 2024.
  • Quarter analysis of 5 years shows Silence Therapeutics' Capital Expenditures stood at $2.8 million in 2021, then crashed by 88.5% to $324901.1 in 2022, then crashed by 66.0% to $110462.5 in 2023, then tumbled by 43.87% to $62000.0 in 2024, then plummeted by 95.16% to $3000.0 in 2025.
  • Its Capital Expenditures stands at $3000.0 for Q3 2025, versus $48000.0 for Q2 2025 and $4000.0 for Q1 2025.